XTL Biopharmaceuticals Ltd.
XTLB
$2.92
$0.031.04%
NASDAQ
| 12/31/2025 | 09/30/2025 | 12/31/2024 | 06/30/2024 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 405.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 405.00K | -- | -- |
| Cost of Revenue | -- | -- | 448.00K | -- | -- |
| Gross Profit | -- | -- | -43.00K | -- | -- |
| SG&A Expenses | -- | -- | 737.00K | 415.00K | 238.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | 1.22M | 421.00K | 251.00K |
| Operating Income | -- | -- | -812.00K | -421.00K | -251.00K |
| Income Before Tax | -- | -- | -385.00K | -704.00K | -919.00K |
| Income Tax Expenses | -- | -- | -130.00K | -- | -- |
| Earnings from Continuing Operations | -- | -- | -255.00K | -704.00K | -919.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -255.00K | -704.00K | -919.00K |
| EBIT | -- | -- | -812.00K | -421.00K | -251.00K |
| EBITDA | -- | -- | -762.30K | -- | -250.80K |
| EPS Basic | -- | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | -- | -- | 0.00 | -- | -- |
| EPS Diluted | -- | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | -- | -- | 0.00 | -- | -- |
| Average Basic Shares Outstanding | 896.17M | -- | 883.67M | 544.91M | 544.91M |
| Average Diluted Shares Outstanding | 896.17M | 883.67M | 883.67M | 544.91M | 544.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |